Ivadrabine for CHF

In this large placebo controlled trial of patients with CHF (EF<35%), they were randomized to ivadrabine or placebo, and the intervention group had significantly lower incidence of the primary outcome (CV death or hospitalized CHF) (24% vs 29% at about 2 year follow up). Although not yet approved by the FDA, once approved this drug will likely become a part of the drug cocktail for patients with systolic heart failure (abstract)

This entry was posted in Cardiology. Bookmark the permalink.

Comments are closed.